# EDGAR Filing Document

**Accession Number:** 0001966494
**File Stem:** 0001610717-25-000297
**Filing Date:** 2025-8
**Character Count:** 9177
**Document Hash:** 530de098424993aca836f01e4f998498
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001610717-25-000297.hdr.sgml**: 20250819

**ACCESSION NUMBER**: 0001610717-25-000297

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250818

**FILED AS OF DATE**: 20250819

**DATE AS OF CHANGE**: 20250819

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Radhakrishnan Anup
- **CENTRAL INDEX KEY:** 0001999930

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41859
- **FILM NUMBER:** 251232356

**MAIL ADDRESS:**
- **STREET 1:** C/O CARGO THERAPEUTICS, INC.
- **STREET 2:** 1900 ALAMEDA DE LAS PULGAS, SUITE 350
- **CITY:** SAN MATEO
- **STATE:** CA
- **ZIP:** 94403
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CARGO Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001966494
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 844080422
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 835 INDUSTRIAL ROAD, SUITE 400
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070
- **BUSINESS PHONE:** 650-499-8950

**MAIL ADDRESS:**
- **STREET 1:** 835 INDUSTRIAL ROAD, SUITE 400
- **CITY:** SAN CARLOS
- **STATE:** CA
- **ZIP:** 94070

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Radhakrishnan Anup<br><sub>(Last) (First) (Middle)</sub><br>C/O CARGO THERAPEUTICS, INC.<br>835 INDUSTRIAL ROAD, SUITE 400<br><sub>(Street)</sub><br>SAN CARLOS, CA 94070<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-08-18 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_See Remarks_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CARGO Therapeutics, Inc. [ CRGX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-08-18 |  | U |  | 57345<sup>(1)(2)</sup> | D | $4.379 | 63436 | D |  |
| Common Stock | 2025-08-19 |  | D |  | 63436<sup>(3)(4)</sup> | D | $4.379 | 0 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $1.09 | 2025-08-19 |  | D |  |  | 14679 | <sup>(5)(6)</sup> | 2032-10-06 | Common Stock | 14679 | <sup>(5)(6)</sup> | 0 | D |  |

---

### Footnotes:

(1) Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 7, 2025, by and among CARGO Therapeutics, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VII, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On August 18, 2025, Parent and Merger Sub completed a tender offer (the "Tender Offer") pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $4.379 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]

(2) [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, effective as of August 19, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").

(3) Pursuant to the terms of the Merger Agreement, immediately prior to the time at which Parent first irrevocably accepts for purchase the Shares tendered in the Tender Offer, each restricted stock unit award with respect to Shares that is, at the time of determination, subject to vesting or forfeiture conditions ("RSU Award") that is outstanding as of immediately prior thereto, shall (a) accelerate and become fully vested, and (b) by virtue of the Merger automatically (except as otherwise provided in the Merger Agreement) and without any action on the part of the Issuer, Parent or the holder thereof, be canceled and terminated and converted into the right to receive [continues to Footnote 4]

(4) [continues from Footnote 3] (i) an amount in cash without interest, subject to any applicable tax withholding, equal to the product of the number of Shares underlying such RSU Award immediately prior to the Effective Time and $4.379 in cash, plus (ii) one CVR with respect to each Share subject to such RSU Award immediately prior to the Effective Time.

(5) As of immediately prior to and conditioned upon the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the Effective Time of the Merger, was canceled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the Effective Time [continues to Footnote 6]

(6) [continues from Footnote 5] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was canceled for no consideration.

**Remarks:**
Title: Interim Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

**Signature:** /s/ Halley Gilbert, as attorney-in-fact for Anup Radhakrishnan  
**Date:** 2025-08-19

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**